<?xml version="1.0" encoding="UTF-8"?><!-- This information is licensed under the Queen's Printer License of British Columbia found: www.bclaws.ca/standards/2014/QP-License_1.0.html. Please review the license terms carefully. --><act:act xmlns:act="http://www.gov.bc.ca/2013/legislation/act" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bcl="http://www.gov.bc.ca/2013/bclegislation" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:in="http://www.qp.gov.bc.ca/2013/inline" xmlns:fun="http://www.bclaws.ca/xslt/functions" xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table" xmlns:reg="http://www.gov.bc.ca/2013/legislation/regulation" id="18035" xsi:schemaLocation="http://www.gov.bc.ca/2013/legislation/act http://standards.qp.gov.bc.ca/standards/2013/act_1.0.xsd">
  <act:title>Opioid Damages and Health Care Costs Recovery Act</act:title>
  <act:chapter>35</act:chapter>
  <act:yearenacted>2018</act:yearenacted>
  <act:assentedto>October 31, 2018</act:assentedto>
  <act:currency>
    <act:tlcDirPath>667588372/1866418823/879785046</act:tlcDirPath>
    <act:tlc>E3tlc18035</act:tlc>
  </act:currency>
  <act:content>
    <bcl:section id="d1e28">
      <bcl:marginalnote>Definitions and interpretation</bcl:marginalnote>
      <bcl:num>1</bcl:num>
      <bcl:subsection id="d1e36">
        <bcl:num>1</bcl:num>
        <bcl:text>In this Act:</bcl:text>
        <bcl:definition id="d1e37">
          <bcl:text>
            <in:term>active ingredient</in:term> means an active ingredient set out in the Schedule;</bcl:text>
        </bcl:definition>
        <bcl:definition id="d1e43">
          <bcl:text>
            <in:term>consultant</in:term> means a person who provides advisory services</bcl:text>
          <bcl:paragraph id="d1e49">
            <bcl:num>a</bcl:num>
            <bcl:text>to a wholesaler in relation to the distribution, sale or offering for sale of opioid products, or</bcl:text>
          </bcl:paragraph>
          <bcl:paragraph id="d1e56">
            <bcl:num>b</bcl:num>
            <bcl:text>to a manufacturer in relation to the sale of active ingredients or opioid products;</bcl:text>
          </bcl:paragraph>
        </bcl:definition>
        <bcl:definition id="d1e44">
          <bcl:text>
            <in:term>cost of health care benefits</in:term> means,</bcl:text>
          <bcl:paragraph id="d1e51">
            <bcl:num>a</bcl:num>
            <bcl:text>in relation to an action under section 2 (1), the sum of</bcl:text>
            <bcl:subparagraph id="d1e82">
              <bcl:num>i</bcl:num>
              <bcl:text> the present value of the total expenditure by the government for health care benefits provided for insured persons as a result of opioid-related disease, injury or illness or the risk of opioid-related disease, injury or illness, and</bcl:text>
            </bcl:subparagraph>
            <bcl:subparagraph id="d1e89">
              <bcl:num>ii</bcl:num>
              <bcl:text>the present value of the estimated total expenditure by the government for health care benefits that could reasonably be expected to be provided for those insured persons as a result of opioid-related disease, injury or illness or the risk of opioid-related disease, injury or illness, and</bcl:text>
            </bcl:subparagraph>
          </bcl:paragraph>
          <bcl:paragraph id="d1e60">
            <bcl:num>b</bcl:num>
            <bcl:text>in relation to an action under section 2.1 (1), the sum of</bcl:text>
            <bcl:subparagraph id="d1e103">
              <bcl:num>i</bcl:num>
              <bcl:text>the present value of the total expenditure by the government of Canada for health care benefits provided for insured persons as a result of opioid-related disease, injury or illness or the risk of opioid-related disease, injury or illness, and</bcl:text>
            </bcl:subparagraph>
            <bcl:subparagraph id="d1e110">
              <bcl:num>ii</bcl:num>
              <bcl:text>the present value of the estimated total expenditure by the government of Canada for health care benefits that could reasonably be expected to be provided for those insured persons as a result of opioid-related disease, injury or illness or the risk of opioid-related disease, injury or illness;</bcl:text>
            </bcl:subparagraph>
          </bcl:paragraph>
        </bcl:definition>
        <bcl:definition id="d1e70">
          <bcl:text>
            <in:term>disease, injury or illness</in:term> includes problematic substance use, addiction and general deterioration of health;</bcl:text>
        </bcl:definition>
        <bcl:definition id="d1e78">
          <bcl:text>
            <in:term>health care benefits</in:term> means,</bcl:text>
          <bcl:paragraph id="d1e138">
            <bcl:num>a</bcl:num>
            <bcl:text>in relation to an action under section 2 (1),</bcl:text>
            <bcl:subparagraph id="d1e85">
              <bcl:num>i</bcl:num>
              <bcl:text>benefits as defined under the <bcl:link resource="leg" xlink:href="/legislation/96204_01" xlink:type="locator"><in:doc>Hospital Insurance Act</in:doc></bcl:link>,</bcl:text>
            </bcl:subparagraph>
            <bcl:subparagraph id="d1e98">
              <bcl:num>ii</bcl:num>
              <bcl:text>benefits as defined under the <bcl:link resource="leg" xlink:href="/legislation/14008" xlink:type="locator"><in:doc>Laboratory Services Act</in:doc></bcl:link>,</bcl:text>
            </bcl:subparagraph>
            <bcl:subparagraph id="d1e111">
              <bcl:num>iii</bcl:num>
              <bcl:text>benefits as defined under the <bcl:link resource="leg" xlink:href="/legislation/96286_01" xlink:type="locator"><in:doc>Medicare Protection Act</in:doc></bcl:link>,</bcl:text>
            </bcl:subparagraph>
            <bcl:subparagraph id="d1e124">
              <bcl:num>iv</bcl:num>
              <bcl:text>benefits as defined under the <bcl:link resource="leg" xlink:href="/legislation/12022_01" xlink:type="locator"><in:doc>Pharmaceutical Services Act</in:doc></bcl:link>,</bcl:text>
            </bcl:subparagraph>
            <bcl:subparagraph id="d1e139">
              <bcl:num>v</bcl:num>
              <bcl:text>payments made by the government under the <bcl:link resource="leg" xlink:href="/legislation/96070_01" xlink:type="locator"><in:doc>Continuing Care Act</in:doc></bcl:link>, and</bcl:text>
            </bcl:subparagraph>
            <bcl:subparagraph id="d1e151">
              <bcl:num>vi</bcl:num>
              <bcl:text>other expenditures by the government, made directly or through one or more agents or other intermediate bodies, for programs, services, benefits or similar matters associated with disease, injury or illness, and</bcl:text>
            </bcl:subparagraph>
          </bcl:paragraph>
          <bcl:paragraph id="d1e208">
            <bcl:num>b</bcl:num>
            <bcl:text>in relation to an action under section 2.1 (1), expenditures by the government of Canada for programs, services, benefits or similar matters associated with disease, injury or illness;</bcl:text>
          </bcl:paragraph>
        </bcl:definition>
        <bcl:definition id="d1e162">
          <bcl:text>
            <in:term>insured person</in:term> means</bcl:text>
          <bcl:paragraph id="d1e169">
            <bcl:num>a</bcl:num>
            <bcl:text>a person, including a deceased person, for whom health care benefits have been provided, or</bcl:text>
          </bcl:paragraph>
          <bcl:paragraph id="d1e178">
            <bcl:num>b</bcl:num>
            <bcl:text>a person for whom health care benefits could reasonably be expected to be provided;</bcl:text>
          </bcl:paragraph>
        </bcl:definition>
        <bcl:definition id="d1e188">
          <bcl:text>
            <in:term>joint venture</in:term> means an association of 2 or more persons, if</bcl:text>
          <bcl:paragraph id="d1e195">
            <bcl:num>a</bcl:num>
            <bcl:text>the relationship among the persons does not constitute a corporation, partnership or trust, and</bcl:text>
          </bcl:paragraph>
          <bcl:paragraph id="d1e204">
            <bcl:num>b</bcl:num>
            <bcl:text>the persons each have an undivided interest in assets of the association;</bcl:text>
          </bcl:paragraph>
        </bcl:definition>
        <bcl:definition id="d1e214">
          <bcl:text>
            <in:term>manufacture</in:term> includes, for an opioid product, the production, assembly and packaging of the opioid product;</bcl:text>
        </bcl:definition>
        <bcl:definition id="d1e222">
          <bcl:text>
            <in:term>manufacturer</in:term> means a person who manufactures or has manufactured an active ingredient or opioid product and a person who, in the past or currently,</bcl:text>
          <bcl:paragraph id="d1e229">
            <bcl:num>a</bcl:num>
            <bcl:text>causes, directly or indirectly, through arrangements with contractors, subcontractors, licensees, franchisees or others, the manufacture of an active ingredient or opioid product,</bcl:text>
          </bcl:paragraph>
          <bcl:paragraph id="d1e238">
            <bcl:num>b</bcl:num>
            <bcl:text>for any fiscal year of the person, derives at least 10% of revenues, determined on a consolidated basis in accordance with generally accepted accounting principles in Canada, from the manufacture or promotion of active ingredients or opioid products by that person or by other persons,</bcl:text>
          </bcl:paragraph>
          <bcl:paragraph id="d1e247">
            <bcl:num>c</bcl:num>
            <bcl:text>engages in or causes, directly or indirectly, other persons to engage in promoting an active ingredient or opioid product, or</bcl:text>
          </bcl:paragraph>
          <bcl:paragraph id="d1e256">
            <bcl:num>d</bcl:num>
            <bcl:text>is a trade association primarily engaged in</bcl:text>
            <bcl:subparagraph id="d1e264">
              <bcl:num>i</bcl:num>
              <bcl:text>advancing the interests of manufacturers,</bcl:text>
            </bcl:subparagraph>
            <bcl:subparagraph id="d1e273">
              <bcl:num>ii</bcl:num>
              <bcl:text>promoting an active ingredient or opioid product, or</bcl:text>
            </bcl:subparagraph>
            <bcl:subparagraph id="d1e282">
              <bcl:num>iii</bcl:num>
              <bcl:text>causing, directly or indirectly, other persons to engage in promoting an active ingredient or opioid product;</bcl:text>
            </bcl:subparagraph>
          </bcl:paragraph>
        </bcl:definition>
        <bcl:definition id="d1e293">
          <bcl:text>
            <in:term>opioid product</in:term> means any product that contains</bcl:text>
          <bcl:paragraph id="d1e300">
            <bcl:num>a</bcl:num>
            <bcl:text>a drug or active ingredient set out in the Schedule, or</bcl:text>
          </bcl:paragraph>
          <bcl:paragraph id="d1e309">
            <bcl:num>b</bcl:num>
            <bcl:text>a drug or active ingredient prescribed by regulation;</bcl:text>
          </bcl:paragraph>
        </bcl:definition>
        <bcl:definition id="d1e319">
          <bcl:text>
            <in:term>opioid-related disease, injury or illness</in:term> means disease, injury or illness caused or contributed to by an individual's use or exposure to an opioid product, whether the opioid product is</bcl:text>
          <bcl:paragraph id="d1e326">
            <bcl:num>a</bcl:num>
            <bcl:text>in the form in which it was manufactured,</bcl:text>
          </bcl:paragraph>
          <bcl:paragraph id="d1e335">
            <bcl:num>b</bcl:num>
            <bcl:text>combined with another drug or substance, or</bcl:text>
          </bcl:paragraph>
          <bcl:paragraph id="d1e344">
            <bcl:num>c</bcl:num>
            <bcl:text>used, or in the case of exposure is present, in a form or manner other than</bcl:text>
            <bcl:subparagraph id="d1e352">
              <bcl:num>i</bcl:num>
              <bcl:text>as prescribed or advised by a practitioner, or</bcl:text>
            </bcl:subparagraph>
            <bcl:subparagraph id="d1e361">
              <bcl:num>ii</bcl:num>
              <bcl:text>as recommended by the manufacturer of that opioid product;</bcl:text>
            </bcl:subparagraph>
          </bcl:paragraph>
        </bcl:definition>
        <bcl:definition id="d1e373">
          <bcl:text>
            <in:term>opioid-related wrong</in:term> means</bcl:text>
          <bcl:paragraph id="d1e380">
            <bcl:num>a</bcl:num>
            <bcl:text>a tort that is committed in British Columbia by a manufacturer, wholesaler or consultant and that causes or contributes to opioid-related disease, injury or illness, or</bcl:text>
          </bcl:paragraph>
          <bcl:paragraph id="d1e389">
            <bcl:num>b</bcl:num>
            <bcl:text>in an action under section 2 (1) or 2.1 (1), a breach, by a manufacturer, wholesaler or consultant, of a common law, equitable or statutory duty or obligation owed to persons in British Columbia who have used or been exposed to or might use or be exposed to an opioid product;</bcl:text>
          </bcl:paragraph>
        </bcl:definition>
        <bcl:definition id="d1e399">
          <bcl:text>
            <in:term>person</in:term> includes a trust, joint venture or trade association;</bcl:text>
        </bcl:definition>
        <bcl:definition id="d1e407">
          <bcl:text>
            <in:term>practitioner</in:term> means a person who</bcl:text>
          <bcl:paragraph id="d1e414">
            <bcl:num>a</bcl:num>
            <bcl:text>is authorized under the <bcl:link resource="leg" xlink:href="/legislation/00_96183_01" xlink:type="locator"><in:doc>Health Professions Act</in:doc></bcl:link> or the <bcl:link resource="leg" xlink:href="/legislation/10015_01" xlink:type="locator"><in:doc>Veterinarians Act</in:doc></bcl:link> to prescribe or advise on the therapeutic value, contents and hazards of a drug within the meaning of the <bcl:link resource="leg" xlink:href="/legislation/03077_01" xlink:type="locator"><in:doc>Pharmacy Operations and Drug Scheduling Act</in:doc></bcl:link>, and</bcl:text>
          </bcl:paragraph>
          <bcl:paragraph id="d1e435">
            <bcl:num>b</bcl:num>
            <bcl:text>is not prohibited from prescribing a drug that is an opioid product;</bcl:text>
          </bcl:paragraph>
        </bcl:definition>
        <bcl:definition id="d1e445">
          <bcl:text>
            <in:term>promote</in:term> or <in:term>promotion</in:term> includes, for an opioid product,</bcl:text>
          <bcl:paragraph id="d1e455">
            <bcl:num>a</bcl:num>
            <bcl:text>the marketing of the opioid product, whether direct or indirect,</bcl:text>
          </bcl:paragraph>
          <bcl:paragraph id="d1e464">
            <bcl:num>b</bcl:num>
            <bcl:text>the distribution or sale of the opioid product, and</bcl:text>
          </bcl:paragraph>
          <bcl:paragraph id="d1e473">
            <bcl:num>c</bcl:num>
            <bcl:text>any research with respect to the opioid product;</bcl:text>
          </bcl:paragraph>
        </bcl:definition>
        <bcl:definition id="d1e483">
          <bcl:text>
            <in:term>type of opioid product</in:term> means an opioid product in the form of a pill, a capsule, an oral liquid, a powder, an injectable, a topical or a combination of any of these;</bcl:text>
        </bcl:definition>
        <bcl:definition id="d1e491">
          <bcl:text>
            <in:term>use or exposure</in:term>, in relation to an opioid product, means ingestion, inhalation, injection, application or assimilation of the opioid product, whether intentional or otherwise;</bcl:text>
        </bcl:definition>
        <bcl:definition id="d1e500">
          <bcl:text>
            <in:term>wholesaler</in:term> means a person who distributes, sells or offers for sale opioid products</bcl:text>
          <bcl:paragraph id="d1e506">
            <bcl:num>a</bcl:num>
            <bcl:text>to pharmacies, distributors or other persons for resale, or</bcl:text>
          </bcl:paragraph>
          <bcl:paragraph id="d1e515">
            <bcl:num>b</bcl:num>
            <bcl:text>to hospitals, facilities or care centres for patient use.</bcl:text>
          </bcl:paragraph>
        </bcl:definition>
      </bcl:subsection>
      <bcl:subsection id="d1e526">
        <bcl:num>2</bcl:num>
        <bcl:text>The definition of "manufacturer" in subsection (1) does not include</bcl:text>
        <bcl:paragraph id="d1e534">
          <bcl:num>a</bcl:num>
          <bcl:text>an individual,</bcl:text>
        </bcl:paragraph>
        <bcl:paragraph id="d1e543">
          <bcl:num>b</bcl:num>
          <bcl:text>a wholesaler or retailer of opioid products who is not related to</bcl:text>
          <bcl:subparagraph id="d1e551">
            <bcl:num>i</bcl:num>
            <bcl:text>a person who manufactures an opioid product, or</bcl:text>
          </bcl:subparagraph>
          <bcl:subparagraph id="d1e560">
            <bcl:num>ii</bcl:num>
            <bcl:text>a person described in paragraph (a) of the definition of "manufacturer", or</bcl:text>
          </bcl:subparagraph>
        </bcl:paragraph>
        <bcl:paragraph id="d1e570">
          <bcl:num>c</bcl:num>
          <bcl:text>a person who</bcl:text>
          <bcl:subparagraph id="d1e578">
            <bcl:num>i</bcl:num>
            <bcl:text>is a manufacturer only because paragraph (b) or (c) of the definition of "manufacturer" applies to the person, and</bcl:text>
          </bcl:subparagraph>
          <bcl:subparagraph id="d1e587">
            <bcl:num>ii</bcl:num>
            <bcl:text>is not related to</bcl:text>
            <bcl:clause id="d1e595">
              <bcl:num>A</bcl:num>
              <bcl:text>a person who manufactures an opioid product, or</bcl:text>
            </bcl:clause>
            <bcl:clause id="d1e604">
              <bcl:num>B</bcl:num>
              <bcl:text>a person described in paragraphs (a) or (d) of the definition of "manufacturer".</bcl:text>
            </bcl:clause>
          </bcl:subparagraph>
        </bcl:paragraph>
      </bcl:subsection>
      <bcl:subsection id="d1e616">
        <bcl:num>3</bcl:num>
        <bcl:text>For the purposes of subsection (2) of this section, a person is related to another person if, directly or indirectly, the person is</bcl:text>
        <bcl:paragraph id="d1e624">
          <bcl:num>a</bcl:num>
          <bcl:text>an affiliate, as defined in section 1 of the <bcl:link resource="leg" xlink:href="/legislation/02057_00" xlink:type="locator"><in:doc>Business Corporations Act</in:doc></bcl:link>, of the other person, or</bcl:text>
        </bcl:paragraph>
        <bcl:paragraph id="d1e633">
          <bcl:num>b</bcl:num>
          <bcl:text>an affiliate of the other person or an affiliate of an affiliate of the other person.</bcl:text>
        </bcl:paragraph>
      </bcl:subsection>
      <bcl:subsection id="d1e644">
        <bcl:num>4</bcl:num>
        <bcl:text>For the purposes of subsection (3) (b), a person is deemed to be an affiliate of another person if the person</bcl:text>
        <bcl:paragraph id="d1e652">
          <bcl:num>a</bcl:num>
          <bcl:text>is a corporation and the other person, or a group of persons not dealing with each other at arm's length of which the other person is a member, owns a beneficial interest in shares of the corporation</bcl:text>
          <bcl:subparagraph id="d1e660">
            <bcl:num>i</bcl:num>
            <bcl:text>carrying at least 50% of the votes for the election of directors of the corporation, and the votes carried by the shares are sufficient, if exercised, to elect a director of the corporation, or</bcl:text>
          </bcl:subparagraph>
          <bcl:subparagraph id="d1e669">
            <bcl:num>ii</bcl:num>
            <bcl:text>having a fair market value, including a premium for control if applicable, of at least 50% of the fair market value of all the issued and outstanding shares of the corporation, or</bcl:text>
          </bcl:subparagraph>
        </bcl:paragraph>
        <bcl:paragraph id="d1e679">
          <bcl:num>b</bcl:num>
          <bcl:text>is a partnership, trust or joint venture, and the other person, or a group of persons not dealing with each other at arm's length of which the other person is a member, has an ownership interest in the assets of that person that entitles the other person or group of persons to receive at least 50% of the profits or at least 50% of the assets on the dissolution, winding up or termination of the partnership, trust or joint venture.</bcl:text>
        </bcl:paragraph>
      </bcl:subsection>
      <bcl:subsection id="d1e689">
        <bcl:num>5</bcl:num>
        <bcl:text>For the purposes of subsection (3) (b), a person is deemed to be an affiliate of another person if the other person, or a group of persons not dealing with each other at arm's length of which the other person is a member, has any direct or indirect influence that, if exercised, would result in control in fact of that person, except if the other person or group of persons deals at arm's length with that person and derives influence solely as a lender.</bcl:text>
      </bcl:subsection>
      <bcl:subsection id="d1e698">
        <bcl:num>6</bcl:num>
        <bcl:text>For the purposes of determining the market share of a manufacturer for a type of opioid product sold in British Columbia, the court must calculate the manufacturer's market share for the type of opioid product by the following formula:</bcl:text>
        <oasis:table style="1" id="d1e706">
          <oasis:tgroup cols="3">
            <oasis:colspec colname="c1" colnum="1"/>
            <oasis:colspec colname="c2" colnum="2"/>
            <oasis:colspec colname="c3" colnum="3"/>
            <oasis:tbody>
              <oasis:trow>
                <oasis:entry colname="c1" valign="center" rowspan="3">
                  <oasis:line>mms = </oasis:line>
                </oasis:entry>
                <oasis:entry colname="c2">
                  <oasis:line>mm</oasis:line>
                </oasis:entry>
                <oasis:entry colname="c3" valign="center" rowspan="3">
                  <oasis:line>× 100%</oasis:line>
                </oasis:entry>
              </oasis:trow>
              <oasis:trow>
                <oasis:entry colname="c2">
                  <oasis:line>
                    <in:hr/>
                  </oasis:line>
                </oasis:entry>
              </oasis:trow>
              <oasis:trow>
                <oasis:entry colname="c2">
                  <oasis:line>MM</oasis:line>
                </oasis:entry>
              </oasis:trow>
            </oasis:tbody>
          </oasis:tgroup>
        </oasis:table>
        <oasis:table style="4" id="d1e753">
          <oasis:tgroup cols="3">
            <oasis:colspec colname="c1" colnum="1"/>
            <oasis:colspec colname="c2" colnum="2"/>
            <oasis:colspec colname="c3" colnum="3"/>
            <oasis:colspec colname="c4" colnum="4"/>
            <oasis:tbody>
              <oasis:trow>
                <oasis:entry rowspan="4" width="84">
                  <oasis:line> </oasis:line>
                </oasis:entry>
                <oasis:entry colname="c2" valign="top" colspan="3">
                  <oasis:line>where</oasis:line>
                </oasis:entry>
              </oasis:trow>
              <oasis:trow>
                <oasis:entry colname="c2" valign="top">
                  <oasis:line>mms</oasis:line>
                </oasis:entry>
                <oasis:entry colname="c3" valign="top" align="center">
                  <oasis:line/>
                </oasis:entry>
                <oasis:entry colname="c4" valign="top">
                  <oasis:line>is the manufacturer's market share for the type of opioid product from the date of the earliest opioid-related wrong committed by that manufacturer to the date of trial;</oasis:line>
                </oasis:entry>
              </oasis:trow>
              <oasis:trow>
                <oasis:entry colname="c2" valign="top">
                  <oasis:line>mm</oasis:line>
                </oasis:entry>
                <oasis:entry colname="c3" valign="top" align="center">
                  <oasis:line/>
                </oasis:entry>
                <oasis:entry colname="c4" valign="top">
                  <oasis:line>is the quantity of the type of opioid product manufactured by the manufacturer that is distributed, sold or offered for sale within British Columbia from the date of the earliest opioid-related wrong committed by that manufacturer to the date of trial;</oasis:line>
                </oasis:entry>
              </oasis:trow>
              <oasis:trow>
                <oasis:entry colname="c2" valign="top">
                  <oasis:line>MM</oasis:line>
                </oasis:entry>
                <oasis:entry colname="c3" valign="top" align="center">
                  <oasis:line/>
                </oasis:entry>
                <oasis:entry colname="c4" valign="top">
                  <oasis:line>is the quantity of the type of opioid product manufactured by all manufacturers that is purchased or dispensed within British Columbia for the purpose of providing health care benefits from the date of the earliest opioid-related wrong committed by the manufacturer to the date of trial.</oasis:line>
                </oasis:entry>
              </oasis:trow>
            </oasis:tbody>
          </oasis:tgroup>
        </oasis:table>
      </bcl:subsection>
      <bcl:subsection id="d1e699">
        <bcl:num>7</bcl:num>
        <bcl:text>For the purposes of determining the market share of a wholesaler for a type of opioid product sold in British Columbia, the court must calculate the wholesaler's market share for the type of opioid product by the following formula:</bcl:text>
        <oasis:table style="1" id="d1e708">
          <oasis:tgroup cols="3">
            <oasis:colspec colname="c1" colnum="1"/>
            <oasis:colspec colname="c2" colnum="2"/>
            <oasis:colspec colname="c3" colnum="3"/>
            <oasis:tbody>
              <oasis:trow>
                <oasis:entry colname="c1" valign="center" rowspan="3">
                  <oasis:line>wms = </oasis:line>
                </oasis:entry>
                <oasis:entry colname="c2">
                  <oasis:line>wm</oasis:line>
                </oasis:entry>
                <oasis:entry colname="c3" valign="center" rowspan="3">
                  <oasis:line>× 100%</oasis:line>
                </oasis:entry>
              </oasis:trow>
              <oasis:trow>
                <oasis:entry colname="c2">
                  <oasis:line>
                    <in:hr/>
                  </oasis:line>
                </oasis:entry>
              </oasis:trow>
              <oasis:trow>
                <oasis:entry colname="c2">
                  <oasis:line>WW</oasis:line>
                </oasis:entry>
              </oasis:trow>
            </oasis:tbody>
          </oasis:tgroup>
        </oasis:table>
        <oasis:table style="4" id="d1e755">
          <oasis:tgroup cols="3">
            <oasis:colspec colname="c1" colnum="1"/>
            <oasis:colspec colname="c2" colnum="2"/>
            <oasis:colspec colname="c3" colnum="3"/>
            <oasis:colspec colname="c4" colnum="4"/>
            <oasis:tbody>
              <oasis:trow>
                <oasis:entry rowspan="4" width="84">
                  <oasis:line> </oasis:line>
                </oasis:entry>
                <oasis:entry colname="c2" valign="top" colspan="3">
                  <oasis:line>where</oasis:line>
                </oasis:entry>
              </oasis:trow>
              <oasis:trow>
                <oasis:entry colname="c2" valign="top">
                  <oasis:line>wms</oasis:line>
                </oasis:entry>
                <oasis:entry colname="c3" valign="top" align="center">
                  <oasis:line/>
                </oasis:entry>
                <oasis:entry colname="c4" valign="top">
                  <oasis:line>is the wholesaler's market share for the type of opioid product from the date of the earliest opioid-related wrong committed by that wholesaler to the date of trial;</oasis:line>
                </oasis:entry>
              </oasis:trow>
              <oasis:trow>
                <oasis:entry colname="c2" valign="top">
                  <oasis:line>wm</oasis:line>
                </oasis:entry>
                <oasis:entry colname="c3" valign="top" align="center">
                  <oasis:line/>
                </oasis:entry>
                <oasis:entry colname="c4" valign="top">
                  <oasis:line>is the quantity of the type of opioid product that is distributed, sold or offered for sale by the wholesaler within British Columbia from the date of the earliest opioid-related wrong committed by that wholesaler to the date of trial;</oasis:line>
                </oasis:entry>
              </oasis:trow>
              <oasis:trow>
                <oasis:entry colname="c2" valign="top">
                  <oasis:line>WW</oasis:line>
                </oasis:entry>
                <oasis:entry colname="c3" valign="top" align="center">
                  <oasis:line/>
                </oasis:entry>
                <oasis:entry colname="c4" valign="top">
                  <oasis:line>is the quantity of the type of opioid product that is distributed, sold or offered for sale within British Columbia for the purpose of providing health care benefits from the date of the earliest opioid-related wrong committed by the wholesaler to the date of trial.</oasis:line>
                </oasis:entry>
              </oasis:trow>
            </oasis:tbody>
          </oasis:tgroup>
        </oasis:table>
      </bcl:subsection>
    </bcl:section>
    <bcl:section id="d1e815">
      <bcl:marginalnote>Direct action by government</bcl:marginalnote>
      <bcl:num>2</bcl:num>
      <bcl:subsection id="d1e823">
        <bcl:num>1</bcl:num>
        <bcl:text>The government has a direct and distinct action against a manufacturer, wholesaler or consultant to recover the cost of health care benefits caused or contributed to by an opioid-related wrong.</bcl:text>
      </bcl:subsection>
      <bcl:subsection id="d1e832">
        <bcl:num>2</bcl:num>
        <bcl:text>An action under subsection (1) is brought by the government in its own right and not on the basis of a subrogated claim.</bcl:text>
      </bcl:subsection>
      <bcl:subsection id="d1e841">
        <bcl:num>3</bcl:num>
        <bcl:text>In an action under subsection (1), the government may recover the cost of health care benefits whether or not there has been any recovery by other persons who have suffered damage caused or contributed to by the opioid-related wrong committed by the defendant.</bcl:text>
      </bcl:subsection>
      <bcl:subsection id="d1e851">
        <bcl:num>4</bcl:num>
        <bcl:text>In an action under subsection (1), the government may recover the cost of health care benefits</bcl:text>
        <bcl:paragraph id="d1e859">
          <bcl:num>a</bcl:num>
          <bcl:text>for particular individual insured persons, or</bcl:text>
        </bcl:paragraph>
        <bcl:paragraph id="d1e868">
          <bcl:num>b</bcl:num>
          <bcl:text>on an aggregate basis, for a population of insured persons</bcl:text>
        </bcl:paragraph>
        <bcl:text>who have suffered damage caused or contributed to by the use of or exposure to a type of opioid product.</bcl:text>
      </bcl:subsection>
      <bcl:subsection id="d1e881">
        <bcl:num>5</bcl:num>
        <bcl:text>If the government seeks in an action under subsection (1) to recover the cost of health care benefits on an aggregate basis,</bcl:text>
        <bcl:paragraph id="d1e889">
          <bcl:num>a</bcl:num>
          <bcl:text>it is not necessary</bcl:text>
          <bcl:subparagraph id="d1e897">
            <bcl:num>i</bcl:num>
            <bcl:text>to identify particular individual insured persons,</bcl:text>
          </bcl:subparagraph>
          <bcl:subparagraph id="d1e906">
            <bcl:num>ii</bcl:num>
            <bcl:text>to prove the cause of opioid-related disease, injury or illness in any particular individual insured person, or</bcl:text>
          </bcl:subparagraph>
          <bcl:subparagraph id="d1e915">
            <bcl:num>iii</bcl:num>
            <bcl:text>to prove the cost of health care benefits for any particular individual insured person,</bcl:text>
          </bcl:subparagraph>
        </bcl:paragraph>
        <bcl:paragraph id="d1e925">
          <bcl:num>b</bcl:num>
          <bcl:text>the health care records and documents of particular individual insured persons or the documents relating to the provision of health care benefits for particular individual insured persons are not compellable except as provided under a rule of law, practice or procedure that requires the production of documents relied on by an expert witness,</bcl:text>
        </bcl:paragraph>
        <bcl:paragraph id="d1e934">
          <bcl:num>c</bcl:num>
          <bcl:text>a person is not compellable to answer questions with respect to the health of, or the provision of health care benefits for, particular individual insured persons,</bcl:text>
        </bcl:paragraph>
        <bcl:paragraph id="d1e944">
          <bcl:num>d</bcl:num>
          <bcl:text>despite paragraphs (b) and (c) of this subsection, on application by a defendant, the court may order discovery of a statistically meaningful sample of the documents referred to in paragraph (b) of this subsection, and the order must include directions concerning the nature, level of detail and type of information to be disclosed, and</bcl:text>
        </bcl:paragraph>
        <bcl:paragraph id="d1e953">
          <bcl:num>e</bcl:num>
          <bcl:text>if an order is made under paragraph (d) of this subsection, the identity of particular individual insured persons must not be disclosed, and all identifiers that disclose or may be used to trace the names or identities of any particular individual insured persons must be deleted from any documents before the documents are disclosed.</bcl:text>
        </bcl:paragraph>
      </bcl:subsection>
    </bcl:section>
    <bcl:section id="d1e1137">
      <bcl:marginalnote>Direct action by the government of Canada</bcl:marginalnote>
      <bcl:num>2.1</bcl:num>
      <bcl:subsection id="d1e1143">
        <bcl:num>1</bcl:num>
        <bcl:text>The government of Canada has a direct and distinct action against a manufacturer, wholesaler or consultant to recover the cost of health care benefits caused or contributed to by an opioid-related wrong.</bcl:text>
      </bcl:subsection>
      <bcl:subsection id="d1e1150">
        <bcl:num>2</bcl:num>
        <bcl:text>An action under subsection (1) is brought by the government of Canada in its own right and not on the basis of a subrogated claim.</bcl:text>
      </bcl:subsection>
      <bcl:subsection id="d1e1157">
        <bcl:num>3</bcl:num>
        <bcl:text>In an action under subsection (1), the government of Canada may recover the cost of health care benefits whether or not there has been any recovery by other persons who have suffered damage caused or contributed to by the opioid-related wrong committed by the defendant.</bcl:text>
      </bcl:subsection>
      <bcl:subsection id="d1e1165">
        <bcl:num>4</bcl:num>
        <bcl:text>In an action under subsection (1), the government of Canada may recover the cost of health care benefits</bcl:text>
        <bcl:paragraph id="d1e1171">
          <bcl:num>a</bcl:num>
          <bcl:text>for particular individual insured persons, or</bcl:text>
        </bcl:paragraph>
        <bcl:paragraph id="d1e1178">
          <bcl:num>b</bcl:num>
          <bcl:text>on an aggregate basis, for a population of insured persons</bcl:text>
        </bcl:paragraph>
        <bcl:text>who have suffered damage caused or contributed to by the use of or exposure to a type of opioid product.</bcl:text>
      </bcl:subsection>
      <bcl:subsection id="d1e1188">
        <bcl:num>5</bcl:num>
        <bcl:text>If the government of Canada seeks in an action under subsection (1) to recover the cost of health care benefits on an aggregate basis,</bcl:text>
        <bcl:paragraph id="d1e1194">
          <bcl:num>a</bcl:num>
          <bcl:text>it is not necessary</bcl:text>
          <bcl:subparagraph id="d1e1200">
            <bcl:num>i</bcl:num>
            <bcl:text>to identify particular individual insured persons,</bcl:text>
          </bcl:subparagraph>
          <bcl:subparagraph id="d1e1207">
            <bcl:num>ii</bcl:num>
            <bcl:text>to prove the cause of opioid-related disease, injury or illness in any particular individual insured person, or</bcl:text>
          </bcl:subparagraph>
          <bcl:subparagraph id="d1e1214">
            <bcl:num>iii</bcl:num>
            <bcl:text>to prove the cost of health care benefits for any particular individual insured person,</bcl:text>
          </bcl:subparagraph>
        </bcl:paragraph>
        <bcl:paragraph id="d1e1222">
          <bcl:num>b</bcl:num>
          <bcl:text>the health care records and documents of particular individual insured persons or the documents relating to the provision of health care benefits for particular individual insured persons are not compellable except as provided under a rule of law, practice or procedure that requires the production of documents relied on by an expert witness,</bcl:text>
        </bcl:paragraph>
        <bcl:paragraph id="d1e1229">
          <bcl:num>c</bcl:num>
          <bcl:text>a person is not compellable to answer questions with respect to the health of, or the provision of health care benefits for, particular individual insured persons,</bcl:text>
        </bcl:paragraph>
        <bcl:paragraph id="d1e1237">
          <bcl:num>d</bcl:num>
          <bcl:text>despite paragraphs (b) and (c) of this subsection, on application by a defendant, the court may order discovery of a statistically meaningful sample of the documents referred to in paragraph (b) of this subsection, and the order must include directions concerning the nature, level of detail and type of information to be disclosed, and</bcl:text>
        </bcl:paragraph>
        <bcl:paragraph id="d1e1244">
          <bcl:num>e</bcl:num>
          <bcl:text>if an order is made under paragraph (d) of this subsection, the identity of particular individual insured persons must not be disclosed, and all identifiers that disclose or may be used to trace the names or identities of any particular individual insured persons must be deleted from any documents before the documents are disclosed.</bcl:text>
        </bcl:paragraph>
      </bcl:subsection>
    </bcl:section>
    <bcl:section id="d1e964">
      <bcl:marginalnote>Recovery of cost of health care benefits on aggregate basis</bcl:marginalnote>
      <bcl:num>3</bcl:num>
      <bcl:subsection id="d1e972">
        <bcl:num>1</bcl:num>
        <bcl:text>In an action under section 2 (1) or 2.1 (1) for the recovery of the cost of health care benefits on an aggregate basis, subsection (2) of this section applies if the government, or the government of Canada, as the case may be, proves, on a balance of probabilities, that, in respect of a type of opioid product,</bcl:text>
        <bcl:paragraph id="d1e980">
          <bcl:num>a</bcl:num>
          <bcl:text>the defendant breached a common law, equitable or statutory duty or obligation owed to insured persons who have used or been exposed to or might use or be exposed to the type of opioid product,</bcl:text>
        </bcl:paragraph>
        <bcl:paragraph id="d1e989">
          <bcl:num>b</bcl:num>
          <bcl:text>using the type of opioid product can cause or contribute to disease, injury or illness, and</bcl:text>
        </bcl:paragraph>
        <bcl:paragraph id="d1e998">
          <bcl:num>c</bcl:num>
          <bcl:text>during all or part of the period of the breach referred to in paragraph (a) of this subsection, the type of opioid product, manufactured or promoted by the defendant, was offered for distribution or sale in British Columbia.</bcl:text>
        </bcl:paragraph>
      </bcl:subsection>
      <bcl:subsection id="d1e1008">
        <bcl:num>2</bcl:num>
        <bcl:text>Subject to subsections (1) and (4), the court must presume that</bcl:text>
        <bcl:paragraph id="d1e1016">
          <bcl:num>a</bcl:num>
          <bcl:text>the population of insured persons who used or were exposed to the type of opioid product manufactured or promoted by the defendant would not have used or been exposed to the product but for the breach referred to in subsection (1) (a), and</bcl:text>
        </bcl:paragraph>
        <bcl:paragraph id="d1e1025">
          <bcl:num>b</bcl:num>
          <bcl:text>the use or exposure described in paragraph (a) of this subsection caused or contributed to disease, injury or illness or the risk of disease, injury or illness in a portion of the population described in paragraph (a) of this subsection.</bcl:text>
        </bcl:paragraph>
      </bcl:subsection>
      <bcl:subsection id="d1e1035">
        <bcl:num>3</bcl:num>
        <bcl:text>If the presumptions under subsection (2) (a) and (b) apply,</bcl:text>
        <bcl:paragraph id="d1e1043">
          <bcl:num>a</bcl:num>
          <bcl:text>the court must determine on an aggregate basis the cost of health care benefits provided after the date of the breach referred to in subsection (1) (a) resulting from use or exposure to the type of opioid product, and</bcl:text>
        </bcl:paragraph>
        <bcl:paragraph id="d1e1052">
          <bcl:num>b</bcl:num>
          <bcl:text>each defendant to which the presumptions apply is liable for the proportion of the aggregate cost referred to in paragraph (a) of this subsection equal to its market share in the type of opioid product.</bcl:text>
        </bcl:paragraph>
      </bcl:subsection>
      <bcl:subsection id="d1e1063">
        <bcl:num>4</bcl:num>
        <bcl:text>The amount of a defendant's liability assessed under subsection (3) (b) may be reduced, or the proportions of liability assessed under subsection (3) (b) readjusted among the defendants, to the extent that a defendant proves, on a balance of probabilities, that the breach referred to in subsection (1) (a) did not cause or contribute to the use or exposure referred to in subsection (2) (a) or to the disease, injury or illness or risk of disease, injury or illness referred to in subsection (2) (b).</bcl:text>
      </bcl:subsection>
    </bcl:section>
    <bcl:section id="d1e1073">
      <bcl:marginalnote>Joint and several liability in an action under section 2 (1) or 2.1 (1)</bcl:marginalnote>
      <bcl:num>4</bcl:num>
      <bcl:subsection id="d1e1081">
        <bcl:num>1</bcl:num>
        <bcl:text>Two or more defendants in an action under section 2 (1) or 2.1 (1) are jointly and severally liable for the cost of health care benefits if</bcl:text>
        <bcl:paragraph id="d1e1089">
          <bcl:num>a</bcl:num>
          <bcl:text>those defendants jointly breached a duty or obligation described in the definition of "opioid-related wrong" in section 1 (1), and</bcl:text>
        </bcl:paragraph>
        <bcl:paragraph id="d1e1098">
          <bcl:num>b</bcl:num>
          <bcl:text>as a consequence of the breach described in paragraph (a) of this subsection, at least one of those defendants is held liable in the action under section 2 (1) or 2.1 (1) for the cost of those health care benefits.</bcl:text>
        </bcl:paragraph>
      </bcl:subsection>
      <bcl:subsection id="d1e1108">
        <bcl:num>2</bcl:num>
        <bcl:text>For purposes of an action under section 2 (1) or 2.1 (1), 2 or more manufacturers, wholesalers or consultants, whether or not they are defendants in the action, are deemed to have jointly breached a duty or obligation described in the definition of "opioid-related wrong" in section 1 (1) if</bcl:text>
        <bcl:paragraph id="d1e1116">
          <bcl:num>a</bcl:num>
          <bcl:text>one or more of those manufacturers, wholesalers or consultants are held to have breached the duty or obligation, and</bcl:text>
        </bcl:paragraph>
        <bcl:paragraph id="d1e1125">
          <bcl:num>b</bcl:num>
          <bcl:text>at common law, in equity or under an enactment, those manufacturers, wholesalers or consultants would be held</bcl:text>
          <bcl:subparagraph id="d1e1133">
            <bcl:num>i</bcl:num>
            <bcl:text>to have conspired or acted in concert with respect to the breach,</bcl:text>
          </bcl:subparagraph>
          <bcl:subparagraph id="d1e1142">
            <bcl:num>ii</bcl:num>
            <bcl:text>to have acted in a principal and agent relationship with each other with respect to the breach, or</bcl:text>
          </bcl:subparagraph>
          <bcl:subparagraph id="d1e1151">
            <bcl:num>iii</bcl:num>
            <bcl:text>to be jointly or vicariously liable for the breach if damages would have been awarded to a person who suffered damages as a consequence of the breach.</bcl:text>
          </bcl:subparagraph>
        </bcl:paragraph>
      </bcl:subsection>
    </bcl:section>
    <bcl:section id="d1e1163">
      <bcl:marginalnote>Population-based evidence to establish causation and quantify damages or cost</bcl:marginalnote>
      <bcl:num>5</bcl:num>
      <bcl:text>Statistical information and information derived from epidemiological, sociological and other relevant studies, including information derived from sampling, is admissible as evidence for the purposes of establishing causation and quantifying damages or the cost of health care benefits respecting an opioid-related wrong in an action brought</bcl:text>
      <bcl:paragraph id="d1e1174">
        <bcl:num>a</bcl:num>
        <bcl:text>by or on behalf of a person, in the person's own name or as a member of a class of persons under the <bcl:link resource="leg" xlink:href="/legislation/96050_01" xlink:type="locator"><in:doc>Class Proceedings Act</in:doc></bcl:link>,</bcl:text>
      </bcl:paragraph>
      <bcl:paragraph id="d1e1187">
        <bcl:num>b</bcl:num>
        <bcl:text>by the government under section 2 (1), or</bcl:text>
      </bcl:paragraph>
      <bcl:paragraph id="d1e1189">
        <bcl:num>c</bcl:num>
        <bcl:text>by the government of Canada under section 2.1 (1).</bcl:text>
      </bcl:paragraph>
    </bcl:section>
    <bcl:section id="d1e1198">
      <bcl:marginalnote>Limitation periods</bcl:marginalnote>
      <bcl:num>6</bcl:num>
      <bcl:subsection id="d1e1206">
        <bcl:num>1</bcl:num>
        <bcl:text>No action that is commenced by the government within 2 years after the coming into force of this subsection for the recovery of the cost of health care benefits, or for damages, alleged to have been caused or contributed to by an opioid-related wrong, is barred under the <bcl:link resource="leg" xlink:href="/legislation/12013_01" xlink:type="locator"><in:doc>Limitation Act</in:doc></bcl:link>.</bcl:text>
      </bcl:subsection>
      <bcl:subsection id="d1e1511">
        <bcl:num>1.1</bcl:num>
        <bcl:text>No action that is commenced by the government of Canada within two years after the coming into force of this subsection for the recovery of the cost of health care benefits is barred under the <bcl:link resource="leg" xlink:href="/legislation/12013_01" xlink:type="locator"><in:doc>Limitation Act</in:doc></bcl:link>.</bcl:text>
      </bcl:subsection>
      <bcl:subsection id="d1e1215">
        <bcl:num>2</bcl:num>
        <bcl:text>Any action described in subsection (1) or (1.1) of this section for damages alleged to have been caused or contributed to by an opioid-related wrong is revived if the action was dismissed before the coming into force of this section merely because it was held by a court to be barred or extinguished by the <bcl:link resource="leg" xlink:href="/legislation/12013_01" xlink:type="locator"><in:doc>Limitation Act</in:doc></bcl:link>.</bcl:text>
      </bcl:subsection>
    </bcl:section>
    <bcl:section id="d1e1228">
      <bcl:marginalnote>Liability based on risk contribution</bcl:marginalnote>
      <bcl:num>7</bcl:num>
      <bcl:subsection id="d1e1238">
        <bcl:num>1</bcl:num>
        <bcl:text>This section applies to an action for the recovery of the cost of health care benefits, or for damages, alleged to have been caused or contributed to by an opioid-related wrong, other than an action for the recovery of the cost of health care benefits on an aggregate basis.</bcl:text>
      </bcl:subsection>
      <bcl:subsection id="d1e1246">
        <bcl:num>2</bcl:num>
        <bcl:text>If the government, or the government of Canada, as the case may be, is unable to establish which defendant caused or contributed to the use or exposure described in paragraph (b) and, as a result of a breach of a common law, equitable or statutory duty or obligation,</bcl:text>
        <bcl:paragraph id="d1e1254">
          <bcl:num>a</bcl:num>
          <bcl:text>one or more defendants causes or contributes to a risk of disease, injury or illness by making a type of opioid product available to insured persons, and</bcl:text>
        </bcl:paragraph>
        <bcl:paragraph id="d1e1263">
          <bcl:num>b</bcl:num>
          <bcl:text>an insured person has used or been exposed to the type of opioid product referred to in paragraph (a) and suffers disease, injury or illness as a result of the use or exposure,</bcl:text>
        </bcl:paragraph>
        <bcl:text>the court may find each defendant that caused or contributed to the risk of disease, injury or illness liable for a proportion of the damages or cost of health care benefits incurred, equal to the proportion of its contribution to that risk of disease, injury or illness.</bcl:text>
      </bcl:subsection>
      <bcl:subsection id="d1e1276">
        <bcl:num>3</bcl:num>
        <bcl:text>The court may consider the following in apportioning liability under subsection (2):</bcl:text>
        <bcl:paragraph id="d1e1284">
          <bcl:num>a</bcl:num>
          <bcl:text>the length of time a defendant engaged in the conduct that caused or contributed to the risk of disease, injury or illness;</bcl:text>
        </bcl:paragraph>
        <bcl:paragraph id="d1e1293">
          <bcl:num>b</bcl:num>
          <bcl:text>the market share a defendant had in the type of opioid product that caused or contributed to the risk of disease, injury or illness;</bcl:text>
        </bcl:paragraph>
        <bcl:paragraph id="d1e1302">
          <bcl:num>c</bcl:num>
          <bcl:text>the degree of potency of the opioid product manufactured or promoted by a defendant;</bcl:text>
        </bcl:paragraph>
        <bcl:paragraph id="d1e1312">
          <bcl:num>d</bcl:num>
          <bcl:text>the amount spent by a defendant on promoting the type of opioid product that caused or contributed to the risk of disease, injury or illness;</bcl:text>
        </bcl:paragraph>
        <bcl:paragraph id="d1e1321">
          <bcl:num>e</bcl:num>
          <bcl:text>the degree to which a defendant collaborated or acted in concert with other manufacturers, wholesalers or consultants in any conduct that caused, contributed to or aggravated the risk of disease, injury or illness;</bcl:text>
        </bcl:paragraph>
        <bcl:paragraph id="d1e1330">
          <bcl:num>f</bcl:num>
          <bcl:text>the extent to which a defendant conducted tests and studies to determine the risk of disease, injury or illness resulting from use of or exposure to the type of opioid product;</bcl:text>
        </bcl:paragraph>
        <bcl:paragraph id="d1e1339">
          <bcl:num>g</bcl:num>
          <bcl:text>the extent to which a defendant assumed a leadership role in manufacturing or promoting the type of opioid product;</bcl:text>
        </bcl:paragraph>
        <bcl:paragraph id="d1e1348">
          <bcl:num>h</bcl:num>
          <bcl:text>the efforts a defendant made to warn practitioners and the public about the risk of disease, injury or illness resulting from use of or exposure to the type of opioid product;</bcl:text>
        </bcl:paragraph>
        <bcl:paragraph id="d1e1357">
          <bcl:num>i</bcl:num>
          <bcl:text>the extent to which a defendant continued manufacturing or promoting the type of opioid product after it knew or ought to have known the risk of disease, injury or illness resulting from use of or exposure to the type of opioid product;</bcl:text>
        </bcl:paragraph>
        <bcl:paragraph id="d1e1367">
          <bcl:num>j</bcl:num>
          <bcl:text>the extent to which a defendant continued promoting the type of opioid product after it knew or ought to have known that the amount or dosage of the type of opioid product promoted did not reasonably reflect the health needs of the population of insured persons who were likely to use or be exposed to the type of opioid product;</bcl:text>
        </bcl:paragraph>
        <bcl:paragraph id="d1e1376">
          <bcl:num>k</bcl:num>
          <bcl:text>affirmative steps that a defendant took to reduce the risk of disease, injury or illness to the public;</bcl:text>
        </bcl:paragraph>
        <bcl:paragraph id="d1e1385">
          <bcl:num>l</bcl:num>
          <bcl:text>other considerations considered relevant by the court.</bcl:text>
        </bcl:paragraph>
      </bcl:subsection>
    </bcl:section>
    <bcl:section id="d1e1683">
      <bcl:marginalnote>Joint and several liability of directors and officers</bcl:marginalnote>
      <bcl:num>7.1</bcl:num>
      <bcl:subsection id="d1e1689">
        <bcl:num>1</bcl:num>
        <bcl:text>A director or officer of a corporation who directs, authorizes, assents to, acquiesces in or participates in an opioid-related wrong committed by the corporation is jointly and severally liable with the corporation for the cost of health care benefits, or damages, caused or contributed to by the opioid-related wrong.</bcl:text>
      </bcl:subsection>
      <bcl:subsection id="d1e1696">
        <bcl:num>2</bcl:num>
        <bcl:text>Subsection (1) applies whether or not an action against the corporation for recovery of the cost of health care benefits, or for damages, has been commenced or concluded.</bcl:text>
      </bcl:subsection>
      <bcl:subsection id="d1e1703">
        <bcl:num>3</bcl:num>
        <bcl:text>A director or officer is not liable under subsection (1) if the director or officer proves, on a balance of probabilities, that the director or officer</bcl:text>
        <bcl:paragraph id="d1e1709">
          <bcl:num>a</bcl:num>
          <bcl:text>did not know, and in the exercise of reasonable diligence could not have known, that the corporation was committing an opioid-related wrong, or</bcl:text>
        </bcl:paragraph>
        <bcl:paragraph id="d1e1716">
          <bcl:num>b</bcl:num>
          <bcl:text>exercised reasonable diligence to prevent the corporation from committing the opioid-related wrong.</bcl:text>
        </bcl:paragraph>
      </bcl:subsection>
    </bcl:section>
    <bcl:section id="d1e1396">
      <bcl:marginalnote>Apportionment of liability in opioid-related wrongs</bcl:marginalnote>
      <bcl:num>8</bcl:num>
      <bcl:subsection id="d1e1404">
        <bcl:num>1</bcl:num>
        <bcl:text>This section does not apply to a defendant in respect of whom the court has made a finding of liability under section 7.</bcl:text>
      </bcl:subsection>
      <bcl:subsection id="d1e1413">
        <bcl:num>2</bcl:num>
        <bcl:text>A defendant who is found liable for an opioid-related wrong may commence, against one or more of the defendants found liable for that wrong in the same action, an action or proceeding for contribution toward the cost of health care benefits or the payment of damages caused or contributed to by that wrong.</bcl:text>
      </bcl:subsection>
      <bcl:subsection id="d1e1422">
        <bcl:num>3</bcl:num>
        <bcl:text>Subsection (2) of this section applies whether or not the defendant commencing an action or proceeding under that subsection has paid all or any of the cost of health care benefits or the damages caused or contributed to by the opioid-related wrong.</bcl:text>
      </bcl:subsection>
      <bcl:subsection id="d1e1432">
        <bcl:num>4</bcl:num>
        <bcl:text>In an action or proceeding described in subsection (2) of this section, the court may apportion liability and order contribution among each of the defendants in accordance with the considerations listed in section 7 (3).</bcl:text>
      </bcl:subsection>
    </bcl:section>
    <bcl:section id="d1e1442">
      <bcl:marginalnote>Regulations</bcl:marginalnote>
      <bcl:num>9</bcl:num>
      <bcl:subsection id="d1e1450">
        <bcl:num>1</bcl:num>
        <bcl:text>The Lieutenant Governor in Council may make regulations referred to in section 41 of the <bcl:link resource="leg" xlink:href="/legislation/96238_01" xlink:type="locator"><in:doc>Interpretation Act</in:doc></bcl:link>.</bcl:text>
      </bcl:subsection>
      <bcl:subsection id="d1e1463">
        <bcl:num>2</bcl:num>
        <bcl:text>Without limiting subsection (1) of this section, the Lieutenant Governor in Council may make regulations prescribing drugs for the purposes of paragraph (b) of the definition of "opioid product" in section 1 (1).</bcl:text>
      </bcl:subsection>
    </bcl:section>
    <bcl:section id="d1e1473">
      <bcl:marginalnote>Retroactive effect</bcl:marginalnote>
      <bcl:num>10</bcl:num>
      <bcl:text>A provision of this Act has the retroactive effect necessary to give the provision full effect for all purposes, including allowing an action to be brought under section 2 (1) or 2.1 (1) arising from an opioid-related wrong, whenever the opioid-related wrong occurred.</bcl:text>
    </bcl:section>
    <bcl:section id="d1e1485">
      <bcl:marginalnote>If proceedings already commenced</bcl:marginalnote>
      <bcl:num>11</bcl:num>
      <bcl:subsection id="d1e1493">
        <bcl:num>1</bcl:num>
        <bcl:text>If the government has commenced a proceeding in relation to an opioid-related wrong and the proceeding is ongoing as of the date this section comes into force,</bcl:text>
        <bcl:paragraph id="d1e1501">
          <bcl:num>a</bcl:num>
          <bcl:text>the proceeding continues in accordance with this Act,</bcl:text>
        </bcl:paragraph>
        <bcl:paragraph id="d1e1510">
          <bcl:num>b</bcl:num>
          <bcl:text>for the purposes of section 4 of the <bcl:link resource="leg" xlink:href="/legislation/96050_01" xlink:type="locator"><in:doc>Class Proceedings Act</in:doc></bcl:link>, the government may bring an action on behalf of a class consisting of</bcl:text>
          <bcl:subparagraph id="d1e1518">
            <bcl:num>i</bcl:num>
            <bcl:text>one or more of the government of Canada and the government of a jurisdiction within Canada, and</bcl:text>
          </bcl:subparagraph>
          <bcl:subparagraph id="d1e1527">
            <bcl:num>ii</bcl:num>
            <bcl:text>a federal or provincial government payment agency that makes reimbursement for the cost of services that are in the nature of health care benefits within the meaning of this Act,</bcl:text>
          </bcl:subparagraph>
        </bcl:paragraph>
        <bcl:paragraph id="d1e1537">
          <bcl:num>c</bcl:num>
          <bcl:text>a procedure completed, and an order made, before this section comes into force continues to have effect unless</bcl:text>
          <bcl:subparagraph id="d1e1545">
            <bcl:num>i</bcl:num>
            <bcl:text>it would be inconsistent with this Act, or</bcl:text>
          </bcl:subparagraph>
          <bcl:subparagraph id="d1e1554">
            <bcl:num>ii</bcl:num>
            <bcl:text>the court orders otherwise, and</bcl:text>
          </bcl:subparagraph>
        </bcl:paragraph>
        <bcl:paragraph id="d1e1565">
          <bcl:num>d</bcl:num>
          <bcl:text>a procedure that began but was not completed before this section comes into force must be completed in accordance with this Act.</bcl:text>
        </bcl:paragraph>
      </bcl:subsection>
      <bcl:subsection id="d1e1575">
        <bcl:num>2</bcl:num>
        <bcl:text>Nothing in subsection (1) (b) of this section prevents a member of the class described in that provision from opting out of the proceeding in accordance with section 16 of the <bcl:link resource="leg" xlink:href="/legislation/96050_01" xlink:type="locator"><in:doc>Class Proceedings Act</in:doc></bcl:link>.</bcl:text>
      </bcl:subsection>
    </bcl:section>
    <bcl:section id="d1e1590">
      <bcl:marginalnote> Effect of existing agreements</bcl:marginalnote>
      <bcl:num>12</bcl:num>
      <bcl:subsection id="d1e1598">
        <bcl:num>1</bcl:num>
        <bcl:text>In subsections (2) and (3) of this section, <in:term>proceeding</in:term> means a proceeding</bcl:text>
        <bcl:paragraph id="d1e1609">
          <bcl:num>a</bcl:num>
          <bcl:text>in relation to an action taken under section 2 (1) of this Act, or</bcl:text>
        </bcl:paragraph>
        <bcl:paragraph id="d1e1618">
          <bcl:num>b</bcl:num>
          <bcl:text>continued as described in section 11 of this Act.</bcl:text>
        </bcl:paragraph>
      </bcl:subsection>
      <bcl:subsection id="d1e1628">
        <bcl:num>2</bcl:num>
        <bcl:text>Despite any prior agreement that purports to bind the government in relation to compensation arising from an opioid-related wrong,</bcl:text>
        <bcl:paragraph id="d1e1636">
          <bcl:num>a</bcl:num>
          <bcl:text>the government is not barred from commencing or continuing a proceeding,</bcl:text>
        </bcl:paragraph>
        <bcl:paragraph id="d1e1645">
          <bcl:num>b</bcl:num>
          <bcl:text>the evidence that may be brought against a party to the agreement in the course of a proceeding is not limited, and</bcl:text>
        </bcl:paragraph>
        <bcl:paragraph id="d1e1654">
          <bcl:num>c</bcl:num>
          <bcl:text>the liability of, or the amount of compensation payable by, a party to the agreement in relation to an opioid-related wrong that is the subject of a proceeding is not limited.</bcl:text>
        </bcl:paragraph>
      </bcl:subsection>
      <bcl:subsection id="d1e1664">
        <bcl:num>3</bcl:num>
        <bcl:text>If an agreement described in subsection (2) of this section has been finalized by receiving the consent of all parties to the agreement and all necessary court approvals, if any, before the date this Act receives Royal Assent, any compensation received by the government under the agreement must be deducted from any compensation received by the government as a result of a proceeding.</bcl:text>
      </bcl:subsection>
      <bcl:subsection id="d1e1674">
        <bcl:num>4</bcl:num>
        <bcl:text>No compensation is payable by the government and proceedings must not be commenced or continued to claim compensation from the government or to obtain a declaration that compensation is payable by the government as a result of the voiding of an agreement described in subsection (2) of this section.</bcl:text>
      </bcl:subsection>
    </bcl:section>
    <bcl:conseqhead>
      <bcl:text>Consequential Amendment</bcl:text>
      <bcl:num>13</bcl:num>
      <bcl:conseqnote>
        <bcl:editorialnote>
          <in:em>[Note: See Table of Legislative Changes for the status of section 13.]</in:em>
        </bcl:editorialnote>
      </bcl:conseqnote>
      <oasis:table style="1" id="d0e5229">
        <oasis:tgroup cols="3">
          <oasis:colspec colname="c1" colnum="1" align="center" border="0"/>
          <oasis:colspec colname="c2" colnum="2" align="center" border="0"/>
          <oasis:colspec colname="c3" colnum="3" align="center" border="0"/>
          <oasis:thead>
            <oasis:trow>
              <oasis:entry colname="c1" align="right">
                <oasis:line>
                  <in:strong>Section(s)</in:strong>
                </oasis:line>
              </oasis:entry>
              <oasis:entry colname="c2" width="35">
                <oasis:line>
                  <in:strong> </in:strong>
                </oasis:line>
              </oasis:entry>
              <oasis:entry colname="c3">
                <oasis:line>
                  <in:strong>Affected Act</in:strong>
                </oasis:line>
              </oasis:entry>
            </oasis:trow>
          </oasis:thead>
          <oasis:tbody>
            <oasis:trow>
              <oasis:entry colname="c1" align="right">
                <oasis:line>
                  <in:em>13</in:em>
                </oasis:line>
              </oasis:entry>
              <oasis:entry colname="c2" width="35">
                <oasis:line> </oasis:line>
              </oasis:entry>
              <oasis:entry colname="c3">
                <oasis:line>
                  <bcl:link resource="leg" xlink:href="/legislation/E3tlc08027" xlink:type="locator">
                    <in:doc>Health Care Costs Recovery Act</in:doc>
                  </bcl:link>
                </oasis:line>
              </oasis:entry>
            </oasis:trow>
          </oasis:tbody>
        </oasis:tgroup>
      </oasis:table>
    </bcl:conseqhead>
    <bcl:section id="d1e1777">
      <bcl:marginalnote>Commencement</bcl:marginalnote>
      <bcl:num>14</bcl:num>
      <bcl:text>This Act comes into force on the date of Royal Assent.</bcl:text>
    </bcl:section>
    <bcl:schedule id="d1e1789">
      <bcl:scheduletitle>Schedule</bcl:scheduletitle>
      <bcl:centertext>
        <in:em>(Section 1)</in:em>
      </bcl:centertext>
      <bcl:section id="d1e1798">
        <bcl:marginalnote>Opioid products</bcl:marginalnote>
        <bcl:num>1</bcl:num>
        <bcl:text>A product that contains any of the following drugs or active ingredients is an opioid product for the purposes of this Act:</bcl:text>
        <oasis:table style="2" id="d1e1809">
          <oasis:tgroup cols="2">
            <oasis:colspec colname="c1" colnum="1"/>
            <oasis:colspec colname="c2" colnum="2"/>
            <oasis:thead>
              <oasis:trow>
                <oasis:entry colname="c1" valign="top" align="center" width="300">
                  <oasis:line>
                    <in:strong>Drugs or active ingredients</in:strong>
                  </oasis:line>
                </oasis:entry>
                <oasis:entry colname="c1" valign="top" align="center" width="300">
                  <oasis:line>
                    <in:strong>Including but not limited to</in:strong>
                  </oasis:line>
                </oasis:entry>
              </oasis:trow>
            </oasis:thead>
            <oasis:tbody>
              <oasis:trow>
                <oasis:entry colname="c1" valign="top" width="300">
                  <oasis:line>Anileridine</oasis:line>
                </oasis:entry>
                <oasis:entry colname="c1" valign="top" width="300">
                  <oasis:line/>
                </oasis:entry>
              </oasis:trow>
              <oasis:trow>
                <oasis:entry colname="c1" valign="top">
                  <oasis:line>Buprenorphine</oasis:line>
                </oasis:entry>
                <oasis:entry colname="c1" valign="top">
                  <oasis:line>Buprenorphine Hydrochloride</oasis:line>
                </oasis:entry>
              </oasis:trow>
              <oasis:trow>
                <oasis:entry colname="c1" valign="top">
                  <oasis:line>Butorphanol</oasis:line>
                </oasis:entry>
                <oasis:entry colname="c1" valign="top">
                  <oasis:line>Butorphanol Tartrate</oasis:line>
                </oasis:entry>
              </oasis:trow>
              <oasis:trow>
                <oasis:entry colname="c1" valign="top" width="300">
                  <oasis:line>Codeine, except for those products referred to in section 36 (1) of the Narcotic Control Regulations (Canada)</oasis:line>
                </oasis:entry>
                <oasis:entry colname="c1" valign="top" width="300">
                  <oasis:line>Codeine Phosphate</oasis:line>
                </oasis:entry>
              </oasis:trow>
              <oasis:trow>
                <oasis:entry colname="c1" valign="top">
                  <oasis:line>Diacetylmorphine</oasis:line>
                </oasis:entry>
                <oasis:entry colname="c1" valign="top">
                  <oasis:line/>
                </oasis:entry>
              </oasis:trow>
              <oasis:trow>
                <oasis:entry colname="c1" valign="top">
                  <oasis:line>Fentanyl</oasis:line>
                </oasis:entry>
                <oasis:entry colname="c1" valign="top">
                  <oasis:line>Fentanyl Citrate</oasis:line>
                </oasis:entry>
              </oasis:trow>
              <oasis:trow>
                <oasis:entry colname="c1" valign="top">
                  <oasis:line>Hydrocodone</oasis:line>
                </oasis:entry>
                <oasis:entry colname="c1" valign="top">
                  <oasis:line>Hydrocodone Bitartrate</oasis:line>
                </oasis:entry>
              </oasis:trow>
              <oasis:trow>
                <oasis:entry colname="c1" valign="top">
                  <oasis:line>Hydromorphone</oasis:line>
                </oasis:entry>
                <oasis:entry colname="c1" valign="top">
                  <oasis:line>Hydromorphone Hydrochloride</oasis:line>
                </oasis:entry>
              </oasis:trow>
              <oasis:trow>
                <oasis:entry colname="c1" valign="top">
                  <oasis:line>Levorphanol</oasis:line>
                </oasis:entry>
                <oasis:entry colname="c1" valign="top">
                  <oasis:line/>
                </oasis:entry>
              </oasis:trow>
              <oasis:trow>
                <oasis:entry colname="c1" valign="top">
                  <oasis:line>Meperidine</oasis:line>
                </oasis:entry>
                <oasis:entry colname="c1" valign="top">
                  <oasis:line>Meperidine Hydrochloride</oasis:line>
                </oasis:entry>
              </oasis:trow>
              <oasis:trow>
                <oasis:entry colname="c1" valign="top">
                  <oasis:line>Methadone</oasis:line>
                </oasis:entry>
                <oasis:entry colname="c1" valign="top">
                  <oasis:line>Methadone Hydrochloride</oasis:line>
                </oasis:entry>
              </oasis:trow>
              <oasis:trow>
                <oasis:entry colname="c1" valign="top">
                  <oasis:line>Morphine </oasis:line>
                </oasis:entry>
                <oasis:entry colname="c1" valign="top">
                  <oasis:line>Morphine Hydrochloride and Morphine Sulfate</oasis:line>
                </oasis:entry>
              </oasis:trow>
              <oasis:trow>
                <oasis:entry colname="c1" valign="top">
                  <oasis:line>Nalbuphine</oasis:line>
                </oasis:entry>
                <oasis:entry colname="c1" valign="top">
                  <oasis:line/>
                </oasis:entry>
              </oasis:trow>
              <oasis:trow>
                <oasis:entry colname="c1" valign="top">
                  <oasis:line>Normethadone</oasis:line>
                </oasis:entry>
                <oasis:entry colname="c1" valign="top">
                  <oasis:line>Normethadone Hydrochloride</oasis:line>
                </oasis:entry>
              </oasis:trow>
              <oasis:trow>
                <oasis:entry colname="c1" valign="top">
                  <oasis:line>Opium</oasis:line>
                </oasis:entry>
                <oasis:entry colname="c1" valign="top">
                  <oasis:line>Opium and Belladonna</oasis:line>
                </oasis:entry>
              </oasis:trow>
              <oasis:trow>
                <oasis:entry colname="c1" valign="top">
                  <oasis:line>Oxycodone</oasis:line>
                </oasis:entry>
                <oasis:entry colname="c1" valign="top">
                  <oasis:line>Oxycodone Hydrochloride</oasis:line>
                </oasis:entry>
              </oasis:trow>
              <oasis:trow>
                <oasis:entry colname="c1" valign="top">
                  <oasis:line>Oxymorphone</oasis:line>
                </oasis:entry>
                <oasis:entry colname="c1" valign="top">
                  <oasis:line>Oxymorphone Hydrochloride</oasis:line>
                </oasis:entry>
              </oasis:trow>
              <oasis:trow>
                <oasis:entry colname="c1" valign="top">
                  <oasis:line>Pentazocine</oasis:line>
                </oasis:entry>
                <oasis:entry colname="c1" valign="top">
                  <oasis:line>Pentazocine Hydrochloride and Pentazocine Lactate</oasis:line>
                </oasis:entry>
              </oasis:trow>
              <oasis:trow>
                <oasis:entry colname="c1" valign="top">
                  <oasis:line>Propoxyphene</oasis:line>
                </oasis:entry>
                <oasis:entry colname="c1" valign="top">
                  <oasis:line/>
                </oasis:entry>
              </oasis:trow>
              <oasis:trow>
                <oasis:entry colname="c1" valign="top">
                  <oasis:line>Remifentanil</oasis:line>
                </oasis:entry>
                <oasis:entry colname="c1" valign="top">
                  <oasis:line/>
                </oasis:entry>
              </oasis:trow>
              <oasis:trow>
                <oasis:entry colname="c1" valign="top">
                  <oasis:line>Sufentanil</oasis:line>
                </oasis:entry>
                <oasis:entry colname="c1" valign="top">
                  <oasis:line/>
                </oasis:entry>
              </oasis:trow>
              <oasis:trow>
                <oasis:entry colname="c1" valign="top">
                  <oasis:line>Tapentadol</oasis:line>
                </oasis:entry>
                <oasis:entry colname="c1" valign="top">
                  <oasis:line>Tapentadol Hydrochloride</oasis:line>
                </oasis:entry>
              </oasis:trow>
              <oasis:trow>
                <oasis:entry colname="c1" valign="top">
                  <oasis:line>Tramadol</oasis:line>
                </oasis:entry>
                <oasis:entry colname="c1" valign="top">
                  <oasis:line>Tramadol Hydrochloride</oasis:line>
                </oasis:entry>
              </oasis:trow>
            </oasis:tbody>
          </oasis:tgroup>
        </oasis:table>
      </bcl:section>
    </bcl:schedule>
  </act:content>
</act:act>